TNFα and its Receptors in Psoriatic Skin, before and after Treatment with Etanercept
- 1 October 2009
- journal article
- clinical trial
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 22 (4), 961-966
- https://doi.org/10.1177/039463200902200411
Abstract
Psoriasis is a chronic inflammatory skin condition characterized by inflammatory dermal infiltrate and hyperproliferative keratinocytes. The pathogenesis of this disease is mediated by a dysregulation of the innate immunity and cytokine production. Tumor Necrosis Factor alpha (TNFα) is considered the most important cytokine involved in the pathological mechanism of psoriasis. Recently, several therapies have been introduced for the treatment of psoriasis that try to block TNF alpha activity. Among these treatments Etanercept is a fusion protein that specifically targets TNF alpha. We performed a study on twelve psoriatic patients aimed at evaluating the effect of Etanercept treatment on the production and expression of TNFα and its receptors, in lesional and uninvolved psoriatic skin. We demonstrated that after three month of Etanercept treatment at 50 mg/wk, TNF, TNF-RI and TNF-RII immunostaining in lesional and non-lesional skin samples of patients was greatly reduced, suggesting that this treatment not only acts on stable lesional plaques, but also at a very early stage of the disease.Keywords
This publication has 13 references indexed in Scilit:
- TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis PlaquesPublished by The American Association of Immunologists ,2005
- Cytokine profiles during infliximab monotherapy in psoriatic arthritisBritish Journal of Dermatology, 2005
- Psoriasis: dysregulation of innate immunityBritish Journal of Dermatology, 2005
- Etanercept for the treatment of psoriasis and psoriatic arthritisDermatologic Therapy, 2004
- Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritisDermatologic Therapy, 2004
- Biological therapies in the systemic management of psoriasis: International Consensus ConferenceBritish Journal of Dermatology, 2004
- Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiencesBritish Journal of Dermatology, 2004
- Biology of tumor necrosis factor‐α– implications for psoriasisExperimental Dermatology, 2004
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Epidermal T lymphocytes and HLA-DR expression in psoriasisBritish Journal of Dermatology, 1984